Cargando…
TAE226, a dual inhibitor of focal adhesion kinase and insulin‐like growth factor‐I receptor, is effective for Ewing sarcoma
The outcomes for relapsed and metastatic Ewing sarcoma (EWS) is extremely poor. Therefore, it is important to identify the tumor‐specific targets in these intractable diseases. High focal adhesion kinase (FAK) transcript expression levels in EWS cell lines are known. TAE226 is a dual inhibitor of FA...
Autores principales: | Moritake, Hiroshi, Saito, Yusuke, Sawa, Daisuke, Sameshima, Naoki, Yamada, Ai, Kinoshita, Mariko, Kamimura, Sachiyo, Konomoto, Takao, Nunoi, Hiroyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912025/ https://www.ncbi.nlm.nih.gov/pubmed/31692287 http://dx.doi.org/10.1002/cam4.2647 |
Ejemplares similares
-
Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
por: Romito, Ilaria, et al.
Publicado: (2021) -
Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects
por: Romito, Ilaria, et al.
Publicado: (2022) -
EVI1 triggers metabolic reprogramming associated with leukemogenesis and increases sensitivity to L-asparaginase
por: Saito, Yusuke, et al.
Publicado: (2020) -
Increased risk for other cancers in individuals with Ewing sarcoma and their relatives
por: Abbott, Diana, et al.
Publicado: (2019) -
Pharmacological profiling of a dual FAK/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models
por: Fukami, Shigemi, et al.
Publicado: (2019)